Decera Clinical Education APP Podcast

Innovations in NCFBE: Understanding the Patient Burden and Best Practices in Diagnostics

Wed, 18 Jun 2025 18:21:54 +0000

In this podcast, Brett M. Elicker, MD, and David E. Griffith, MD, ATSF, FACCP, FRSM, discuss the pathophysiology of non–cystic fibrosis bronchiectasis (NCFBE), the patient burden, and best practices with diagnosing NCFBE, including:

The vicious vortex of NCFBE (ie, airway dysfunction, inflammation, infection)
Cough as the most significant symptom and burden
Imaging bronchiectasis with classic and inflammatory findings
Differentiating the causes of NCFBE to inform patient care

Presenters

Brett M. Elicker, MD
Professor of Clinical Radiology
Chief, Cardiothoracic Imaging Division
Department of Radiology & Biomedical Imaging
University of California, San Francisco
San Francisco, California

David E. Griffith, MD, ATSF, FACCP, FRSM
Professor of Medicine
Division of Mycobacterial and Respiratory Diseases
Department of Medicine
National Jewish Health
Denver, Colorado

Program page:
https://bit.ly/4mZbYsm

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen Up: Time to Prioritize RSV Vaccination for Adults

support@clinicaloptions.com (Ruth Carrico, Audrey M. Stevenson) — Wed, 11 Jun 2025 14:02:26 +0000

Respiratory Syncytial Virus (RSV) significantly impacts adults, especially those over age 60 and those with chronic conditions.

In this podcast, nurse practitioners Drs. Carrico and Stevenson discuss the underestimated burden of RSV. The podcast also explores practical strategies for increasing vaccine uptake that you can apply to your practice starting today so that you can protect your patients against RSV.

Listen as they discuss:

The Burden of Adult RSV
RSV Vaccines for Adults: Data and Recommendations
RSV Vaccine Uptake
Practical Strategies to Increase RSV Vaccine Uptake

Faculty:

Dr. Ruth Carrico is a family nurse practitioner and senior consultant with Carrico & Ramirez, PLLC focused on infectious diseases, infection prevention and control, and vaccinology. She is based in Louisville, Kentucky and is a Professor, adjunct faculty, with the University of Louisville School Medicine, Division of Infectious Diseases. Dr. Carrico has received training specific for healthcare epidemiology at the Centers for Disease Control and Prevention (CDC) in conjunction with the Rollins School of Public Health at Emory University in Atlanta and the Society for Healthcare Epidemiology of America (SHEA).

Dr. Carrico has worked in the field of infectious diseases and infection control for more than thirty years. Dr. Carrico also maintains a clinical practice focused on vaccines, vaccination, and immunization processes.

Dr. Audrey M. Stevenson is a family nurse practitioner with over 40 years of clinical, public health, and leadership experience.

Dr. Stevenson, who holds a master of public health and master of nursing degrees, received her doctorate in public health from the University of Utah. She formerly worked in public health for over 34 years and was the former Division Director of Family Health and Clinical Services of the Salt Lake County Health Department in Salt Lake City, Utah. She currently works as a consultant and teaches graduate FNP and MPH students at two universities.

Dr. Stevenson is also a member of the statewide vaccine advisory board, where she collaborates on vaccine policies and recommendations for the state. Previously, Dr. Stevenson served as Vaccination Branch Director for the COVID-19 Incident Command for Salt Lake County, where she directed the vaccination strategies for 1.2 million residents of Salt Lake County. She has been a vaccine champion for over 30 years.
Learn more:
Download this practical infographic to help you integrate RSV vaccination into your clinical practice.
https://bit.ly/43mzacq

For more information for nurses, subscribe to the PCE podcast channel on your favorite player!

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Update on the Care of Pediatric Patients With Moderate to Severe Atopic Dermatitis

support@clinicaloptions.com (Evette Whaley, Katie Smiley PA) — Tue, 27 May 2025 13:17:27 +0000

Listen in as Evette Whaley and Katie Smiley PA-C talk about innovative strategies for NPs and PAs to improve treatment for pediatric patients with atopic dermatitis. They discuss how to assess the whole patient and their family to better understand the impact of the disease on their quality of life. They also discuss newer treatments and how they can be incorporated into a comprehensive management plan for pediatric patients and their caregivers.

Presenters:

Evette Whaley
Caregiver
Baltimore, Maryland

Katie Smiley PA-C
Grants & Clinical Director
Program Coordinator, Multidisciplinary Atopic Dermatitis Program
Allergy & Asthma Medical Group
Rady Children’s Hospital
San Diego, California

Link to full program:
https://bit.ly/43svVyJ

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Guidance on Managing Axial Spondyloarthritis and Psoriatic Arthritis to Improve Patient Outcomes and Quality of Life

support@clinicaloptions.com (Alexis Ogdie MD MSCE, Julia Swafford PA-C DFAAPA) — Wed, 29 Jan 2025 21:09:34 +0000

Listen in as rheumatology experts Alexis Ogdie, MD, MSCE, and Julia Swafford, PA-C, DFAAPA, discuss emerging therapies and strategies in managing patients with axial spondyloarthritis or psoriatic arthritis, including:

The current treatment landscape (eg, small molecules, biologics)
Risk factors to consider when prescribing JAK inhibitors
Key considerations regarding comorbidities, especially in addressing depression, anxiety, or social ideation
Nonpharmacologic options to improve treatment outcomes
Shared decision-making strategies to enhance patients’ investment in their care

Presenter:

Alexis Ogdie, MD, MSCE
Director, Penn Psoriatic Arthritis and Spondylarthritis Program
Director, Penn Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania
Philadelphia, Pennsylvania

Julia Swafford, PA-C, DFAAPA
President of SPAR
Bronson Battle Creek Rheumatology Specialists
Battle Creek, Michigan

Link to full program:
bit.ly/4gkTzSv

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How Primary Care Providers Can Expand Their Role in HBV Management

Fri, 26 Apr 2024 16:25:00 +0000

In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:

Engage key stakeholders in the provision of HBV care
Provide HBV management resources to support PCPs who are doing screening
Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBV

Presenters:

Su Wang, MD, MPH, FACP
Medical Director
Center for Asian Health and Viral Hepatitis Programs
Cooperman Barnabas Medical Center
RWJBarnabas-Rutgers Medical Group
Associate Member
Health Care Policy and Aging Research
The Rutgers Institute for Health
Senior Advisor
Global Health, Hepatitis B Foundation
Florham Park, New Jersey

Richard R. Andrews, MD, MPH
President, Houston Viral Hepatitis Task Force
Former Co-Chair, National Task Force on Hepatitis B
Board-Certified Family Medicine
Addiction Medicine Physician
Houston, Texas

Ruth Brogden, MPH
Patient Advocate

Amy S. Tang, MD
Former Co-Chair, National Task Force on Hepatitis B
Director of Immigrant Health
North East Medical Services
San Francisco, California

Link to full program:
https://bit.ly/3TuqFHI

Link to the slides:
https://bit.ly/44hXpHu

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How to Implement Earlier Hepatitis B Treatment

Tue, 26 Mar 2024 18:31:30 +0000

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:

Patient subgroups to consider for treatment outside guideline criteria
Adverse event and cost-effectiveness considerations
Integration of patient perspectives in wider treatment

Presenters:

Mark S. Sulkowski, MD, FIDSA, FAASLD
Professor of Medicine
Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Tatyana Kushner, MD, MSCE
Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York

Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Jacki Chen, PhD
Patient Advocate

Link to full program:
https://bit.ly/3TuqFHI

Link to the slides:
https://bit.ly/4a60GM4

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Art of Multidisciplinary Care for Patients With Metabolic Dysfunction–Associated Steatohepatitis

support@clinicaloptions.com (Arun B. Jesudian MD, Mazen Noureddin MD MHSc) — Wed, 13 Mar 2024 16:49:18 +0000

In this episode, Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapeutics, and management optimization strategies.

Presenters:

Arun B. Jesudian, MD
Associate Professor of Clinical Medicine
Division of Gastroenterology and Hepatology
Weill Cornell Medicine
New York, New York

Mazen Noureddin, MD, MHSc
Professor of Medicine
Houston Methodist Hospital
Director
Houston Research Institute
Houston, Texas

Content based on an online CME program supported by independent educational grants from Novo Nordisk.

To view the full program on “Clinical Pathways: Multidisciplinary Approach to Managing Metabolic Dysfunction‒Associated Steatohepatitis,” including 4 CME/CE-certified text modules with accompanying slidesets, 4 ClincalThought commentaries, and a downloadable infographic resource on the AGA MASLD MASH Clinical Care Pathway, visit clinicaloptions.com or click on the link below.

Link to full program:
https://bit.ly/3Tyu7At

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How to Implement Earlier Hepatitis B and Hepatitis Delta Screening

support@clinicaloptions.com (Practicing Clinicians Exchange) — Fri, 22 Dec 2023 05:00:00 +0000

In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:

Updated CDC recommendations for one-time universal screening for HBV
Addressing patient-, provider-, and system-level barriers to universal HBV screening
Best practices for implementation of HDV screening

Presenters:

Douglas Dieterich, MD
Director, Institute for Liver Medicine

Professor of Medicine

Division of Liver Diseases

Mount Sinai School of Medicine

New York, New York

Camilla S. Graham, MD, MPH
Co-Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts

Robert Wong, MD, MS
Clinical Associate Professor
Division of Gastroenterology and Hepatology
Stanford University School of Medicine
Palo Alto, California

Link to full program:
https://bit.ly/3TuqFHI

Link to the slides:
https://bit.ly/4atS42z

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

2023 Audio Recap: Principles of Outpatient COVID-19 Management

support@clinicaloptions.com (Renslow Sherer MD, Trinh P. Vu PharmD BCIDP) — Wed, 3 May 2023 16:49:18 +0000

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:

Current COVID-19 landscape
Rapid antigen tests and PCR tests
Risk stratification of patients who have a positive SARS-CoV-2 test
Antiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)
Long COVID

Presenters:
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois

Trinh P. Vu, PharmD, BCIDP
Clinical Pharmacy Specialist in Infectious Diseases
Department of Pharmaceutical Services
Emory University Hospital Midtown
Atlanta, Georgia

To download the slides: bit.ly/3oHKC09

To view the full online program: bit.ly/4201xcO

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Empowering Patients to Choose the Right HIV PrEP for Them

support@clinicaloptions.com (Jona Tanguay MMSc PA-C AAHIVS) — Tue, 25 Apr 2023 11:17:45 +0000

In this episode, Jona Tanguay, MMSc, PA-C, AAHIVS discusses considerations to review with patients to empower them to make their own informed choices in PrEP selection, including:

Leveraging PrEP options with unique dosing schedules and/or routes such as long-acting cabotegravir and on-demand 2-1-1 FTC/TDF
Differences in adverse effect profiles between 4 PrEP options
Potential for HIV resistance
Requirements for compliance and monitoring
Evidence in populations with various acquisition behaviors
Drug interaction implications

Faculty:

Jona Tanguay, MMSc, PA-C, AAHIVS

Health Care Provider and HIV Specialist

Whitman-Walker Health

Vice President for Education, GLMA: Health Professionals Advancing LGBTQ Equality

Clinical Instructor, Yale University School of Nursing

Washington, DC

Link to full program: https://bit.ly/41WF54o

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Spinal Muscular Atrophy: Improved Recognition and Management of a Rare Disease

Tue, 18 Apr 2023 15:00:00 +0000

In this episode, Julie Parsons, MD, discusses the genetic diagnosis of spinal muscular atrophy (SMA), anticipated clinical findings, the importance of newborn screenings, and the next steps to consider after a positive diagnosis is obtained. This high-level overview includes:

SMA as an autosomal recessive disease
Differences in spinal motor neurons (SMN) 1 and 2 at the time of diagnosis and how these drive severity of disease
Important clinical findings in the diagnosis of SMA, as every child may not be identified with newborn screening
The importance of newborn screening and critical next steps and logistical considerations when receiving a positive screen in your practice

Presenters:

Julie Parsons, MD
Co-Director, Neuromuscular Clinic
Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders
Professor of Clinical Pediatrics and Neurology
Children’s Hospital Colorado
Denver, Colorado

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, FPCN
Senior Director of Nursing, Palliative Care
Psychosocial Oncology and Palliative Care
Dana-Farber Cancer Institute
Boston, Massachusetts

Supported by an educational grant from Biogen

Link to full program:
bit.ly/41kw2dK

Link to CME: Claim credit -
bit.ly/40eyBwr

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What’s New in the Treatment of Spinal Muscular Atrophy

Tue, 18 Apr 2023 15:00:00 +0000

In this episode, Dr. Parsons and Dr. Battista discuss current and emerging medical therapies for the treatment of spinal muscular atrophy (SMA). They review safety, efficacy, and monitoring parameters of current agents, as well as adjuct therapies in the medication pipeline. This high-level overview includes:

Review of FDA-approved medical therapies: nusinersen, onasemnogene abeparvovec-xioi, and risdiplam
Discussion of the safety, efficacy, and monitoring parameters for FDA approved medications, as well as adjuctive agents for medication therapy complications
Review of ongoing clinical trials on anti-myostatin medications and discussion of the role these agents would play if approved by the FDA

Presenters:

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, FPCN
Senior Director of Nursing, Palliative Care
Psychosocial Oncology and Palliative Care
Dana-Farber Cancer Institute
Boston, Massachusetts

Supported by an educational grant from Biogen

Link to full program:
bit.ly/41kw2dK

Link to CME: Claim credit -
bit.ly/40fkDKD

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Care Coordination in Spinal Muscular Atrophy

Tue, 18 Apr 2023 15:00:00 +0000

In this episode, Dr. Battista and Dr. Parsons discuss the importance of care guidelines and the multidisciplinary team in the treatment of spinal muscular atrophy (SMA). This overview will include:

The role each member of the interdisciplinary team plays in the care of SMA including physical therapists, occupational therapists, and speech therapists
The importance of continued, ongoing therapy in addition to medication therapy to provide the greatest improvement in SMA care
How to manage transitions in care, including the transition from pediatrics to adulthood and how to include the necessary support teams
The role shared decision-making plays in the treatment of patients with SMA

Presenters:

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, FPCN
Senior Director of Nursing, Palliative Care
Psychosocial Oncology and Palliative Care
Dana-Farber Cancer Institute
Boston, Massachusetts

Supported by an educational grant from Biogen.

Link to full program:
https://bit.ly/43Dmo7q

Link to CME: Claim credit
https://bit.ly/40gulfX

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Evidence and Guidelines for COVID-19 In-Hospital Management—Expert Answers to Frequently Asked Questions on Coinfections and Transitions of Care

support@clinicaloptions.com (Practicing Clinicians Exchange) — Mon, 27 Mar 2023 16:40:00 +0000

In this episode, Vikramjit Mukherjee, MD, and Cameron Smith, MPAS, PA-C, answer audience questions on how best to care for hospitalized patients with COVID-19 from a live, virtual question and answer webinar. This episode includes expert insights on:

Viral coinfections such as influenza and RSV
New data comparing baricitinib and tocilizumab for patients with severe COVID-19
Management of bacterial and fungal coinfection while incorporating antimicrobial stewardship
Tips for transitioning patients out of the ICU and to the medical floor or home

Presenters:

Vikramjit Mukherjee, MD
Assistant Professor
Division of Pulmonary, Critical Care, & Sleep Medicine
New York University School of Medicine
Director
Medical Intensive Care Unit
Bellevue Hospital
New York

Cameron Smith MPAS, PA-C
Lead Advanced Practice Provider
Medical Intensive Care Unit
Bellevue Hospital
New York Health and Hospitals
New York

Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc. Link to full program:
bit.ly/3z52c00

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Evidence and Guidelines for COVID-19 In-Hospital Management—Expert Answers to Frequently Asked Questions on Supportive Care and Escalation of Therapy

support@clinicaloptions.com (Vikramjit Mukherjee, Cameron Smith MPAS) — Mon, 27 Mar 2023 14:00:00 +0000

Supportive care management such as oxygen support, glycemic control, and anticoagulation
Escalation of therapy in patients with worsening oxygen requirements
Use of remdesivir in patients with renal dysfunction
Brief commentary on long COVID

Presenters:

Cameron Smith MPAS, PA-C
Lead Advanced Practice Provider
Medical Intensive Care Unit
Bellevue Hospital
New York Health and Hospitals
New York, New York

Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc.
bit.ly/3z52c00

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tackling Disparities in HIV Prevention

support@clinicaloptions.com (Susan LeLacheur DrPH PA-C AAHIVS) — Thu, 19 Jan 2023 21:30:00 +0000

In this podcast, Susan LeLacheur, DrPH, PA-C, AAHIVS discusses racial disparities in access to HIV prevention (PrEP) and strategies to close these gaps, including:

Incorporating comprehensive sexual history into medical appointments and offering PrEP to all sexually active patients
Increase awareness of PrEP access programs in communities of color
Diversification of the medical workforce

Faculty:

Susan LeLacheur, DrPH, PA-C, AAHIVS

Professor

Department of Physician Assistant Studies

School of Medicine and Health Sciences

The George Washington University

Washington, DC

Link to full program: https://practicingclinicians.com/content/hiv-prevention-resource-center

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Key Concepts and Updates for the Diagnosis and Management of NTM-LD

Tue, 10 Jan 2023 19:00:00 +0000

This podcast episode is part of a multimedia program reviewing the management of nontuberculous mycobacterial lung disease (NTM-LD). Tune in to hear Jennifer Faber-Gerling, RN, MS, CNS, ANP-BC, and Anne O’Donnell, MD, highlight the diagnostic criteria and optimal treatment strategies in patients with NTM-LD. The overview will include:

Recommended assessments and tests to appropriately diagnosis NTM-LD in patients
A summary of the current guidelines for the management of NTM-LD, including appropriate monitoring of medications.
Guidance on how to individualize treatment plans for patients with NTM-LD based on disease and patient characteristics

Presenters:
Jennifer Faber-Gerling, RN, MS, CNS, ANP-BC
Nurse Practitioner
Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, Colorado

Anne O’Donnell, MD
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
Georgetown University Medical Center
Washington, DC

To view other program offerings, including a CE-certified on-demand webcast, a Q&A text module, and to download slides, visit
pce.is/NTM.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Return of the Flu: Prevention and Management Beyond Vaccination in 2022—Expert Answers to Frequently Asked Questions

support@clinicaloptions.com (Tracy Zivin Tutela MD, Daniel Zalinov PA C) — Mon, 9 Jan 2023 21:00:00 +0000

In this episode, Tracy Zivin-Tutela, MD, answers audience questions on how best to care for patients at high risk of complications due to influenza from a live virtual meeting series. This episode includes expert insights on:

Emerging resistance patterns of currently used antivirals
Getting the flu vaccine after treatment with antivirals
Use of antivirals in patients who test positive for flu and COVID-19
Techniques and over-the-counter therapies other than yearly vaccination to avoid severe complications due to the flu
Avoiding dairy after receiving baloxavir
Insurance coverage for antivirals
Considering bacterial and viral coinfection in patients with lung disease
Retreating high-risk patients with antivirals after another flu exposure
Calculating flu rates

Presenter:

Tracy Zivin-Tutela, MD
Attending Physician
Division of Infectious Diseases
Department of Medicine
Los Alamitos Medical Center, Fountain Valley Regional Hospital
New Brunswick, California

Daniel Zalinov, PA-C
Atrium Health
Charlotte, North Carolina

Link to full program:
https://bit.ly/3GMokRC

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Podcast 1: The Case for Early Diagnosis and Treatment for MS

support@clinicaloptions.com (Practicing Clinicians Exchange) — Fri, 30 Dec 2022 18:00:00 +0000

In this episode, Stephen Krieger, MD, and Allison Boyd, MPAS, PA-C, MSCSdiscuss timely recognition of MS, including insights into why early recognition can lead to early treatment, which can decrease the risk of disability progression and produces better outcomes. Challenges discussed include the variable clinical presentation of MS and the lack of specific tests. The experts also discuss how to avoid missed diagnosis and misdiagnosis.

Stephen Krieger, MD: consultant/advisor/speaker: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics; researcher: Biogen, Bristol-Myers Squibb, Novartis, Sanofi.

Allison L. Boyd, MPAS, PA-C, MSCS: consultant/advisor/speaker: EMD Serono.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Podcast 2: What’s New in Disease-Modifying Therapy

support@clinicaloptions.com (Practicing Clinicians Exchange) — Fri, 30 Dec 2022 18:00:00 +0000

In this episode, Stephen Krieger, MD, and Allison Boyd, MPAS, PA-C, MSCSdiscuss the expanding treatment armamentarium for MS, the complexities involved in making treatment selection, patient factors to consider when individualizing treatment, and how best to talk with patients about their options within the context of shared decision-making.

Stephen Krieger, MD: consultant/advisor/speaker: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics; researcher: Biogen, Bristol-Myers Squibb, Novartis, Sanofi.

Allison L. Boyd, MPAS, PA-C, MSCS: consultant/advisor/speaker: EMD Serono.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Podcast 3: MS in the Long Term

support@clinicaloptions.com (Stephen Krieger MD, Allison Boyd MPAS PA-C MSCS) — Wed, 28 Dec 2022 21:15:00 +0000

In this episode, Stephen Krieger, MD, and Allison Boyd, MPAS, PA-C, MSCS discuss the challenges of managing patients with MS over the long-term, including assessment and management of comorbidities management, differentiating relapse from pseudorelapse, telemedicine, and the important role of NPs and PAs in multidisciplinary care.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How I Approach PrEP in Practice

support@clinicaloptions.com (Jason Farley PhD MPH ANP-BC FAAN AACRN) — Tue, 15 Nov 2022 21:00:00 +0000

In this podcast, Jason E. Farley, PhD, MPH, ANP-BC shares his recommendations on the best ways to implement new HIV PrEP guidelines based on his clinical experiences. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

HIV PrEP: Implementing New Guideline Recommendations Into Clinical Practice

support@clinicaloptions.com (Latesha Elopre MD MSPH) — Tue, 9 Aug 2022 14:00:00 +0000

In this podcast, Latesha Elopre, MD, MSPH, discusses how the new CDC recommendations on pre-exposure prophylaxis (PrEP) education, eligibility, and monitoring affect her clinical practice.

Contributors:

Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, Alabama

Latesha Elopre, MD, MSPH, has no relevant financial relationships to disclose.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Improving HIV Prevention in Primary Care: The Evolution of PrEP - Episode 4

Wed, 27 Jul 2022 15:00:00 +0000

In this podcast, Latesha Elopre, MD, MSPH and Jason Farley, PhD, MPH, ANP-BC, FAAN, AACRN answer pressing questions from healthcare professionals who care for patients that may be at risk for HIV infection.

Presenters:

Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, Alabama

Moderator

Jason Farley, PhD, MPH, ANP-BC, FAAN AACRN
Endowed Professor of Nursing Leadership and Innovation
Johns Hopkins University School of Nursing
Director, Center for Infectious Disease and Nursing Innovation
Adult Nurse Practitioner, Infectious Diseases
Johns Hopkins Medicine
Baltimore, Maryland

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Improving HIV Prevention in Primary Care: The Evolution of PrEP - Episode 3

Wed, 27 Jul 2022 14:00:00 +0000

In this podcast, Latesha Elopre, MD, MSPH discusses options for pre-exposure prophylaxis (PrEP). Listen as she explains best practices for the nonpharmacologic prevention of HIV, as well as oral and injectable pharmacologic PrEP options.

Presenters:

Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, Alabama

Moderator

Jason Farley, PhD, MPH, ANP-BC, FAAN, AACRN
Endowed Professor of Nursing Leadership and Innovation
Johns Hopkins University School of Nursing
Director, Center for Infectious Disease and Nursing Innovation
Adult Nurse Practitioner, Infectious Diseases
Johns Hopkins Medicine
Baltimore, Maryland

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Improving HIV Prevention in Primary Care: The Evolution of PrEP - Episode 2

Wed, 27 Jul 2022 13:00:00 +0000

In this podcast, Latesha Elopre, MD, MSPH discusses the new CDC guideline recommendations for pre-exposure prophylaxis (PrEP). Listen as she explains the updated eligibility criteria, assessing indications for PrEP, and best practices for HIV/antibody testing.

Presenter:

Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, Alabama

Moderator

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Improving HIV Prevention in Primary Care: The Evolution of PrEP - Episode 1

Wed, 27 Jul 2022 12:00:00 +0000

In this podcast, Latesha Elopre, MD, MSPH discusses inequities in pre-exposure prophylaxis (PrEP) uptake and the importance of sexual health screening. Additionally, Dr Elopre shares her best practices for receiving an adequate sexual health history from her patients.

Presenters:

Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, Alabama

Moderator

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Management of Atopic Dermatitis in Primary Care and Specialty Settings

Tue, 19 Jul 2022 16:00:00 +0000

This podcast episode is part of a multimedia program discussing the co-management of moderate to severe atopic dermatitis (AD) in the primary care and specialty settings. Tune in to hear Dr Silverberg and NP Victoria Garcia-Albea highlight newly approved agents and the recent expanded labeling of an existing AD therapy, including:

Ruxolitinib, a topical JAK inhibitor for mild to moderate AD approved in 2021
Abrocitinib and upadacitinib, oral JAK inhibitors approved in early 2022 for moderate to severe AD
Tralokinumab, an IL-13 inhibitor available as a subcutaneous injection, which was approved in late 2021 for moderate to severe AD
Expanded approval for use in patients as young as 6 months for dupilumab, a subcutaneous IL-4 receptor α inhibitor

Presenters:

Jonathan Silverberg, MD, PhD, MPH
Associate Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Victoria Garcia-Albea, PNP, DCNP, MSN, BSN, PRN
Director
Lahey Dermatology Nurse Practitioner Training Program
Lahey Hospital and Medical Center
Burlington, Massachusetts

To view other program offerings, including a CE-certified recorded roundtable webcast, a ClinicalThought commentary, and to download slides, visit:
https://bit.ly/3PiupXZ

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

ASCO 2022: What’s New in Mantle Cell Lymphoma

support@clinicaloptions.com (Tycel J Phillips MD, Amy Goodrich RN MSN CRNP-AC) — Thu, 30 Jun 2022 16:00:00 +0000

In this episode, Tycel J. Phillips, MD, and Amy Goodrich, RN, MSN, CRNP-AC, provide expert insights on key data presented at ASCO 2022 for mantle cell lymphoma regarding:

Results from the phase III SHINE study of the addition of ibrutinib the first-line BR followed by rituximab maintenance in older patients with MCL
Updated results from the phase II ZUMA-2 study evaluating brexucabtagene autoleucel for patients with R/R MCL
Results from a phase I/II study of the ROR1 humanized monoclonal antibody, zilovertamab, in combination with ibrutinib for patients with R/R MCL, MZL, or CLL/SLL
Preliminary results from a phase I study of the humanized ROR1xCD3 bispecific antibody, NVG-111, in R/R CLL and MCL after ≥2 previous therapies

Presenters:

Tycel J. Phillips, MD
Maria Reinhardt Decesare Research Professor of Blood Cancers and Bone Marrow Transplantation
Associate Professor of Medicine
University of Michigan
Rogel Cancer Center
Ann Arbor, Michigan

Amy Goodrich, RN, MSN, CRNP-AC
Research Associate, Department of Medicine
Johns Hopkins University
Nurse Practitioner, Department of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Content supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Link to full program, including a downloadable highlights slideset:
https://bit.ly/3yufCU4

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

ASCO 2022: Advances in CLL/SLL

support@clinicaloptions.com (John M Burke MD, Amy Esposito FNP-C) — Thu, 30 Jun 2022 16:00:00 +0000

In this episode, John M. Burke, MD, a leading expert, and Amy Esposito, FNP-C provide expert insights on key data presented at the 2022 ASCO annual conference for CLL/SLL regarding:

Updated response and safety results after 3 years of follow-up from the phase II CAPTIVATE study of ibrutinib and venetoclax in patients with previously untreated CLL
Updated response and remission rates after 4 years of follow-up from a phase II trial of obinutuzumab, ibrutinib, and venetoclax in patients with either treatment-naïve or relapsed/refractory CLL
Progression free survival and safety results after 5 years of follow-up from the ELEVATE-TN phase III study of Acalabrutinib ± Obinutuzumab vs
Obinutuzumab + Chlorambucil as first-line therapy in CLL
Assessments of whether racial and/or ethnic identity, and socioeconomic status are prognostic factors of survival in CLL

Presenter

John M. Burke, MD
Rocky Mountain Cancer Centers
Aurora, Colorado

Moderator

Amy Esposito, FNP-C
Nurse Practitioner
Rocky Mountain Cancer Center
Aurora, Colorado

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Nursing Considerations for CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

support@clinicaloptions.com (Julia LaBarbera MSN RN AGACNP-BC) — Thu, 30 Jun 2022 12:00:00 +0000

In this episode, Julia LaBarbera, MSN, RN, AGACNP-BC, discusses the latest evidence and guidance on how advanced practice providers can optimize patient outcomes with CDK4/6 inhibitors for HR+/HER2- breast cancer. Topics include:

An overview of the monarchE study leading to FDA approval of adjuvant abemaciclib
Key trial data on abemaciclib, palbociclib, and ribociclib for metastatic HR+/HER2- breast cancer
Managing adverse events associated with CDK4/6 inhibitors
Promoting adherence to oral therapy

Presenter:

Julia LaBarbera, MSN, RN, AGACNP-BC
Nurse Practitioner
Division of Hematology/Oncology
Department of Medicine
University of California, Los Angeles
Santa Monica, California

Link to full program:
PCE.is/Onc22

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A Nursing Perspective on PARP Inhibitors in Prostate Cancer

support@clinicaloptions.com (Brenda Martone MSN ANP-BC AOCNP) — Thu, 30 Jun 2022 12:00:00 +0000

In this episode, Brenda Martone, MSN, ANP-BC, AOCNP describes recent evidence on PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) and discusses best practices for incorporating PARP inhibitors into clinical practice. Topics include:

An overview of the PROpel study of olaparib and the TRITON study of rucaparib
FDA-approved indications for olaparib and rucaparib
Genetic and molecular testing for BRCA1/2 and other HRR mutations
Managing adverse events associated with olaparib and rucaparib
Monitoring for and managing anemia
Gastrointestinal side effects
Fatigue
A look at the future of PARP inhibitors in mCRPC with combination approaches of AR-directed therapy and PARP inhibition

Presenter:
Brenda Martone, MSN, ANP-BC, AOCNP
Nurse Practitioner
Division of Genitourinary Oncology
Northwestern Medicine
Chicago, Illinois

Link to full program:
PCE.is/Onc22

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Optimizing Immune Checkpoint Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer

support@clinicaloptions.com (Sandip P Patel MD) — Thu, 30 Jun 2022 12:00:00 +0000

In this episode, Sandip Patel, MD shares his thoughts on optimizing immune checkpoint inhibitor (ICI) therapy in advanced non-small-cell lung cancer (NSCLC) and discusses best practices for individualizing therapy decisions and managing adverse events.

Topics include:

Currently approved ICIs
Role of biomarker and PD-L1 testing in advanced NSCLC
Strategies to individualize ICI treatment for patients with advanced NSCLC
Strategies for identifying and managing immune-related adverse events in patients treated with ICI

Presenter:
Sandip P. Patel, MD
Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California – San Diego
La Jolla, California

Link to full program:
https://bit.ly/39vuCHC

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: An Update from ASCO 2022

support@clinicaloptions.com (Beth Sandy MSN CRNP) — Mon, 27 Jun 2022 20:00:00 +0000

In this episode, Beth Sandy, MSN, CRNP provides her thoughts on key data presented at the 2022 ASCO annual conference relating to immune checkpoint inhibitors in non-small cell lung cancer (NSCLC). Findings covered include:

Survival results after 3 years from the phase III Checkmate 9LA study of nivolumab and ipilimumab combined with 2 cycles of chemotherapy vs chemotherapy in previously untreated advanced NSCLC
Updated survival and safety results after 5 years from the phase III Checkmate 227 study of nivolumab and ipilimumab vs chemotherapy in previously untreated advanced NSCLC, including assessment of a treatment-free interval
Updated analysis from the phase III ATEZO-BRAIN trial of atezolizumab + carboplatin and pemetrexed in patients with advanced NSCLC with untreated brain metastases
Updated overall response analysis from the phase II KEYNOTE-799 study of pembrolizumab with concurrent chemoradiation in unresectable, locally advanced stage III NSCLC
Results from a phase II trial evaluating nivolumab plus ipilimumab vs nivolumab monotherapy following chemoradiation in unresectable stage III NSCLC
Pathological complete response results from the phase II NADIM II study of nivolumab and chemotherapy vs chemotherapy in the neoadjuvant NSCLC setting

Presenter:

Beth Sandy, MSN, CRNP
Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Link to full program:
https://bit.ly/39vuCHC

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Interview With the Experts: Strategies to Overcome SDOH in NVAF Part 1

support@clinicaloptions.com (Keith Ferdinand MD FACC FAHA, David Kountz MD) — Thu, 16 Jun 2022 04:00:00 +0000

In this episode, Keith C. Ferdinand MD, FACC, FAHA, discusses with David S. Kountz, MD, a patient case in which health disparities affected NVAF care and provides strategies to address low health literacy and patient access to direct-acting oral anticoagulant to improve NVAF-related cardiovascular outcomes.

Presenters

Keith C. Ferdinand, MD, FACC, FAHA
Professor of Medicine
Tulane Heart and Vascular Institute
Tulane University School of Medicine
New Orleans, Louisiana

David S. Kountz, MD
Professor of Medicine
Department of Medicine
Hackensack Meridian School of Medicine
Nutley, New Jersey

Link to full program:
https://bit.ly/3xn238i

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Interview with the Experts: Strategies to Overcome SDOH in NVAF Part 2

support@clinicaloptions.com (Keith Ferdinand MD FACC FAHA, David Kountz MD) — Thu, 16 Jun 2022 04:00:00 +0000

In this episode, David S. Kountz, MD, discusses with Keith C. Ferdinand MD, FACC, FAHA, a patient case in which health disparities affected NVAF care and provides patient, provider, and health-system level strategies to address these disparities to improve NVAF-related cardiovascular outcomes.

Presenters

Keith C. Ferdinand, MD, FACC, FAHA
Professor of Medicine
Tulane Heart and Vascular Institute
Tulane University School of Medicine
New Orleans, Louisiana

David S. Kountz, MD
Professor of Medicine
Department of Medicine
Hackensack Meridian School of Medicine
Nutley, New Jersey

Link to full program:
https://bit.ly/3xn238i

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Heading Into Migraine Management

Mon, 13 Jun 2022 04:00:00 +0000

In this podcast episode, 2 migraine experts discuss clinical pearls for individualizing migraine care from diagnosis to ongoing management. They cover patient factors to consider in the differential diagnosis, when choosing an acute treatment, and in making the decision to initiate preventive treatment. This activity is available for CE/CME credit. Claim your credit at pce.is/migraine.

Contributors

Maureen Moriarty, DNP, ANP-BC
Associate Professor
Director
Malek School of Nursing Professions
Marymount University
Arlington, Virginia
Owner
Moriarty Associates
Westminster, Maryland

Dr Moriarty:consultant/advisor/speaker: AbbVie/Allergan, Amgen, Biohaven, Lilly;researcher: Teva.

Karen A. Williams, DNP, FNP-BC, AQH
President
KDW Health Management
Pensacola, Florida

Dr Williams: consultant/advisor/speaker: Biohaven.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Overview of SDOH in NVAF and CV-Related Outcomes

Thu, 26 May 2022 14:40:00 +0000

This podcast is the first in a series of 3 featuring an multidisciplinary panel of expert faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, David S. Kountz, MD, provides a detailed explanation of the atrial fibrillation paradox and data on the impacts of SDOH on NVAF CV-related outcomes.Review the downloadable slideset and full program at: PCE.is/NVAF.

Contributors:

Program Director
Keith C. Ferdinand, MD, FACC, FAHA,has disclosed that he has received consulting fees from Amgen, Boehringer Ingelheim, Medtronic, Novartis, and Sanofi.

Faculty
David S. Kountz, MD, has no relevant conflicts of interest to report.

Laura Ross, PA-C, CLS, has no relevant conflicts of interest to report.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

NVAF Management and Future Directions

Thu, 26 May 2022 14:05:00 +0000

This podcast is the third in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Keith C. Ferdinand, MD, FACC, FAHA, details the effects of SDOH on anticoagulation prescribing in NVAF and provides an overview of areas for future study. Review the downloadable slideset and full program at: PCE.is/NVAF.

Contributors:

Program Director

Keith C. Ferdinand, MD, FACC, FAHA, has disclosed that he has received consulting fees from Amgen, Boehringer Ingelheim, Medtronic, Novartis, and Sanofi.

Faculty

David S. Kountz, MD, has no relevant conflicts of interest to report.

Laura Ross, PA-C, CLS, has no relevant conflicts of interest to report.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Strategies to Overcome SDOH in NVAF

Thu, 26 May 2022 14:00:00 +0000

This podcast is the second in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Laura Ross PA-C, CLS, dives deeper into the impacts of SODH on NVAF care and provides strategies to address to improve patient care and clinical outcomes in NVAF. Review the downloadable slideset and full program at: PCE.is/NVAF.

Contributors:

Program Director
Keith C. Ferdinand, MD, FACC, FAHA, has disclosed that he has received consulting fees from Amgen, Boehringer Ingelheim, Medtronic, Novartis, and Sanofi.

Faculty
David S. Kountz, MD, has no relevant conflicts of interest to report.

Laura Ross, PA-C, CLS, has no relevant conflicts of interest to report.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Strategies for Individualizing Management of Inflammatory Bowel Disease: Episode 3

Mon, 16 May 2022 12:00:00 +0000

This podcast is the third in a series of four featuring IBD specialists Drs Anita Afzali, MD, MPH, FACG, AGAF and Nana Bernasko, DNP, CRNP, WHNP-BC. In this episode, our panel of experts review strategies for individualizing care, medication response challenges, the use of therapeutic drug monitoring, and treatment de-escalation strategies.

Presenters:

Anita Afzali, MD, MPH, FACG, AGAF
Professor of Clinical Medicine
Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease
Medical Director, OSU Inflammatory Bowel Disease Center
Program Director, Advanced Inflammatory Bowel Disease Fellowship
Division of Gastroenterology, Hepatology, and Nutrition
The Ohio State University Wexner Medical Center
Columbus, Ohio

Nana Bernasko, DNP, CRNP, WHNP-BC
Assistant Professor
Division of Gastroenterology and Hepatology
Department of Medicine
Penn State University Medical Center
Hershey, Pennsylvania

The content in this series was adapted from a live CE program supported by educational grants from Amgen, Ferring Pharmaceuticals, Inc., and the Leona M. and Harry B. Helmsley Charitable Trust.

To access the full program, go to
pce.is/IBD

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Strategies for Individualizing Management of Inflammatory Bowel Disease: Episode 1

Mon, 16 May 2022 12:00:00 +0000

This podcast is the first in a series of four featuring IBD specialists Drs Anita Afzali, MD, MPH, FACG, AGAF and Nana Bernasko, DNP, CRNP, WHNP-BC. In this episode, the experts discuss the importance early and accurate diagnosis and classification of IBD plays in choosing appropriate and individualized therapies for disease management.

Presenters:

Nana Bernasko, DNP, CRNP, WHNP-BC
Assistant Professor
Division of Gastroenterology and Hepatology
Department of Medicine
Penn State University Medical Center
Hershey, Pennsylvania

The content in this series was adapted from a live CE program supported by educational grants from Amgen, Ferring Pharmaceuticls, Inc., and the Leona M. and Harry B. Helmsley Charitable Trust.

To access the full program, go to
pce.is/IBD

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Strategies for Individualizing Management of Inflammatory Bowel Disease: Episode 4

support@clinicaloptions.com (Nana Bernasko DNP CRNP WHNP-BC) — Mon, 16 May 2022 12:00:00 +0000

This podcast is the last in a series of four featuring IBD Dr Nana Bernasko, DNP, CRNP, WHNP-BC. In this episode, Dr Bernasko reviews the best practices for collaborating with primary care for optimal health maintenance in IBD patients, including cancer screening, bone health, immunizations, and more.

Presenter:
Nana Bernasko, DNP, CRNP, WHNP-BC
Assistant Professor
Division of Gastroenterology and Hepatology
Department of Medicine
Penn State University Medical Center
Hershey, Pennsylvania

The content in this series was adapted from a live CE program supported by educational grants from Amgen, Ferring Pharmaceuticals, Inc., and the Leona M. and Harry B. Helmsley Charitable Trust.

To access the full program, go to
pce.is/IBD

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Strategies for Individualizing Management of Inflammatory Bowel Disease: Episode 2

Mon, 16 May 2022 12:00:00 +0000

This podcast is the second in a series of four featuring IBD specialists Drs Anita Afzali, MD, MPH, FACG, AGAF and Nana Bernasko, DNP, CRNP, WHNP-BC. Our moderator for the series is Mr Rick Davis, PA-C. In this episode, our panel of experts review available medication options and their current place in therapy according to recent evidence and guideline recommendations.

Presenters:

Nana Bernasko, DNP, CRNP, WHNP-BC
Assistant Professor
Division of Gastroenterology and Hepatology
Department of Medicine
Penn State University Medical Center
Hershey, Pennsylvania

Richard H. Davis, PA-C
Senior Physician Assistant
Division of Gastroenterology, Hepatology, and Nutrition
University of Florida College of Medicine
Gainesville, Florida

The content in this series was adapted from a live CE program supported by educational grants from Amgen, Ferring Pharmaceuticls, Inc., and the Leona M. and Harry B. Helmsley Charitable Trust.

To access the full program, go to
pce.is/IBD

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Getting Ahead of the Pain: Preventive Options for Migraine

Tue, 5 Apr 2022 14:00:00 +0000

In this second of two podcasts, 2 experts in migraine provide clinical pearls focused on preventing migraine. Listen as they discuss patient factors that indicate preventive treatment is warranted, the range of available preventive treatments and their use in practice, and strategies for engaging patients in their care.

This activity is available for CE/CME credit. Claim your credit at pce.is/migraine.

Contributors:

Karen A. Williams, DNP, FNP-BC, AQH
President
KDW Health Management
Pensacola, Florida

Dr Williams: consultant/advisor/speaker: Biohaven.

Maureen Moriarty, DNP, ANP-BC
Associate Professor
Director
Malek School of Nursing Professions
Marymount University
Arlington, Virginia
Owner
Moriarty Associates
Westminster, Maryland

Dr Moriarty: consultant/advisor/speaker: AbbVie/Allergan, Amgen, Biohaven, Lilly; researcher: Teva.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Heading Off the Pain: Acute Treatment of Migraine

Tue, 5 Apr 2022 14:00:00 +0000

In this first of two podcasts, 2 experts in migraine provide valuable information on the differential diagnosis of migraine, including screening tools and techniques to incorporate into your practice. Additionally, they detail acute treatment options ranging from nonpharmacologic to over-the-counter to novel prescription pharmacologic therapies and discuss their use in the acute migraine management paradigm. This activity is available for CE/CME credit. Claim your credit at pce.is/migraine.

Contributors:

Karen A. Williams, DNP, FNP-BC, AQH
President
KDW Health Management
Pensacola, Florida

Dr Williams: consultant/advisor/speaker: Biohaven.

Maureen Moriarty, DNP, ANP-BC
Associate Professor
Director
Malek School of Nursing Professions
Marymount University
Arlington, Virginia
Owner
Moriarty Associates
Westminster, Maryland

Dr Moriarty: consultant/advisor/speaker: AbbVie/Allergan, Amgen, Biohaven, Lilly; researcher: Teva.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New Options for Management of Refractory ITP

Tue, 5 Apr 2022 13:00:00 +0000

In this second of two podcasts, listen as 2 experts discuss novel therapies that target disease pathophysiology, with a focus on individualizing treatment to optimize outcomes for their patients with ITP. Unique considerations of the drug and surgical options are discussed. This activity is available for CE/CME credit. Claim your credit at pce.is/ITP.

Contributors:

Hanny Al-Samkari, MD
Assistant Professor
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts

Christopher Nelson, ACNP-BC, MBA
Nurse Practitioner
Hematology and Oncology
Avera Cancer Institute
Avera St Luke’s Hospital
Aberdeen, South Dakota

Dr Al-Samkari: consultant/advisor/speaker: Argenx, Forma, Moderna, Novartis, Rigel; consultant/research funding (paid to institution): Agios, Amgen, Dova/Sobi.

Mr Nelson: consultant/advisor/speaker: Amgen, AbbVie, AstraZeneca, Bristol-Myers Squibb/Celgene, Beigene, Incyte, Karyopharm, Rigel, Sanofi.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recognition and Initial Management of ITP

Tue, 5 Apr 2022 13:00:00 +0000

In this first of two podcasts, 2 experts discuss risk factors and current recommendations for the diagnostic workup of ITP, and share strategies for initial management of newly diagnosed disease. Topics including corticosteroid overuse, approaches to improve remission rates, and contemporary concerns with COVID vaccination will be covered.. This activity is available for CE/CME credit. Claim your credit at pce.is/ITP.

Contributors:

Christopher Nelson, ACNP-BC, MBA
Nurse Practitioner
Hematology and Oncology
Avera Cancer Institute
Avera St Luke’s Hospital
Aberdeen, South Dakota

Dr Al-Samkari: consultant/advisor/speaker: Argenx, Forma, Moderna, Novartis, Rigel; consultant/research funding (paid to institution): Agios, Amgen, Dova/Sobi.

Mr Nelson: consultant/advisor/speaker: Amgen, AbbVie, AstraZeneca, Bristol-Myers Squibb/Celgene, Beigene, Incyte, Karyopharm, Rigel, Sanofi.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What’s New in Sickle Cell Disease and Vaso-occlusive Episodes

Mon, 4 Apr 2022 14:08:46 +0000

In this second of 2 podcasts episodes on the management of painful vaso-occlusive crises in patients with sickle cell disease, listen to Alison Towerman, RN, MSN, CPNP, and Michael R. DeBaun, MD, MPH, discuss available treatment options for the prevention of painful vaso-occlusive events, and provide emergency department and outpatient setting recommendations on the proper use and indications for hydroxyurea, L-glutamine, and P-selecting blocking antibody crizanlizumab. This activity is available for 0.25 ANCC and 0.25 AAPA credits, with 0.25 credits applicable for pharmacology credit for NPs. To receive credit for this program, go to pce.is/sickle.

Contributors:

Michael R. DeBaun, MD, MPH
Director
Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease
Professor
Pediatrics and Medicine
Vice Chair for Clinical and Translational Research
Department of Pediatrics
J.C. Peterson Chair in Pediatrics
Nashville, Tennessee

Michael R. DeBaun, MD, MPH: consulting, speaker, and advisory board fees: Forma, GBT, Novartis, and Vertix.

Alison Towerman, RN, MSN, CPNP
Pediatric Nurse Practitioner
Department of Pediatrics, Division of Hematology/Oncology
Washington University School of Medicine in St. Louis
St. Louis, Missouri

Ms. Towerman has no relevant financial relationships to disclose.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Current Understanding of Sickle Cell Disease

Mon, 4 Apr 2022 14:08:26 +0000

In this first of 2 podcasts episodes, Alison Towerman, RN, MSN, CPNP, and Michael R. DeBaun, MD, MPH, discuss best practices for the management of painful vaso-occlusive crises (VOCs) in patients with sickle cell disease, review the disease pathophysiology, and provide emergency department and outpatient setting recommendations on nonpharmacologic and pharmacologic management of painful VOCs. This activity is available for 0.25 ANCC and 0.25 AAPA credits, with 0.25 credits applicable for pharmacology credit for NPs. To receive credit for this program, go to pce.is/sickle.

Contributors:

Michael R. DeBaun, MD, MPH: consulting, speaker, and advisory board fees: Forma, GBT, Novartis, and Vertix.

Alison Towerman, RN, MSN, CPNP
Pediatric Nurse Practitioner
Department of Pediatrics, Division of Hematology/Oncology
Washington University School of Medicine in St. Louis
St. Louis, Missouri

Ms. Towerman has no relevant financial relationships to disclose.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Making Sense of the Expanding Options in Metastatic Colorectal Cancer Care: Part 2

Mon, 21 Mar 2022 16:00:00 +0000

In this second of two podcasts, two oncologists discuss subsequent therapy for metastatic colorectal cancer, and review cases of patients with metastatic colorectal cancer to discuss testing for mutations and biomarkers, appropriate selection of treatment regimens, and management. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Joleen Hubbard MD

Cathy Eng, MD

Stephanie Andrews, MS, APRN-C

Ms Andrews: fees for non-CME/CE services: Genentech.

Dr Eng: consulting fees: Amgen, GlaxoSmithKline, Hoopika, Natera; contracted research (paid to institution): Merck, Pfizer.

Dr Hubbard: advisor: BeiGene; advisor/researcher: Bayer, Boston Biomedical, G1 Therapeutics, Hutchison MediPharma, Incyte, Merck, Pionyr Immunotherapeutics, Seagen, Senhwa Pharmaceuticals, Roche, Treos Bio, TriOncology, Trovogene.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Making Sense of the Expanding Options in Metastatic Colorectal Cancer Care: Part 1

Mon, 21 Mar 2022 16:00:00 +0000

In this first of two podcasts, oncologists discuss the latest evidence that informs how they select first-line treatment regimens for patients with metastatic colorectal cancer. Using cases for a patient-centered approach, they explore the recommended testing for mutations and biomarkers that impact metastatic colorectal cancer, how to plan strategies for incorporating novel agents into the treatment of patients and recommended strategies to identify and manage toxicities of novel agents for metastatic colorectal cancer. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Joleen Hubbard MD

Cathy Eng, MD

Stephanie Andrews, MS, APRN-C

Ms Andrews: fees for non-CME/CE services: Genentech.

Dr Eng: consulting fees: Amgen, GlaxoSmithKline, Hoopika, Natera; contracted research (paid to institution): Merck, Pfizer.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

ASCO Genitourinary Cancers Symposium, 2022: A Focus on Prostate Cancer

Thu, 17 Mar 2022 13:00:00 +0000

In this podcast, Dr. Alicia Morgans discusses recent data presented at the 2022 ASCO GU Cancers Symposium, including trials evaluating the use of first-line PARP inhibitors in combination with abiraterone for mCRPC, continuation of enzalutamide after progression, and imaging modalities as predictive and prognostic biomarkers. This activity is available for CE/CME credit. Claim your credit at pce.is/ascogu.

Contributors:

Dr Morgans has disclosed that she has received funds for research support from Atellas, AstraZeneca, Bayer, Myovant, and Pfizer, and consulting fees from AAA, Astellas, AstraZeneca, Bayer, Blue Earth, Clovis, Dendreon, Janssen, Lantheus, Merck, Myovant, Novartis, Pfizer, Sanofi, and Telix.

Ms Martone has no relevant conflicts of interest to report.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Gastric Cancer: New Strategies, New Therapies, New Hope, Part 2

support@clinicaloptions.com (David Ilson MD) — Fri, 25 Feb 2022 15:33:05 +0000

In this second of two podcasts, an expert discuss decision making for subsequent line therapy for advanced gastric cancer, and review cases to illustrate practical considerations, followed by a question-and-answer session. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributor:

David Ilson, MD

Dr Ilson: consulting fees: Aeris, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, Merck, Roche, Taiho.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Gastric Cancer: New Strategies, New Therapies, New Hope, Part 1

support@clinicaloptions.com (David Ilson MD) — Fri, 25 Feb 2022 15:32:56 +0000

In this first of two podcasts, an expert discusses the data supporting their selection of first-line treatments for advanced gastric cancer. A case illustrates key takeaways about molecular markers that can impact choice of therapy in gastric cancer, novel and emerging treatments, and prevention and management of treatment-related toxicities. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributor:

David Ilson, MD

Dr Ilson: consulting fees: Aeris, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, Merck, Roche, Taiho.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

HCC: Current State, Available and Emerging Therapies – Episode 1

Fri, 25 Feb 2022 14:00:00 +0000

In this first episode of two podcasts, Dr. Amit Singal and Dr. Mark Yarchoan discuss the latest data supporting their approach to selecting treatment regimens for patients with HCC, with topics including: the current challenges in the management of HCC, recommended initial workup strategies and the evolving treatment landscape in HCC. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Amit Singal, MD, MS

Mark Yarchoan, MD

Bridget O’Brien, DNP, FNP-BC, AOCNP

Dr Singal: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Roche.

Dr Yarchoan: consulting fees: AstraZeneca, Eisai, Exelixis, Genentech; other financial or material support: Bristol-Myers Squibb, Incyte.

Dr O’Brien: fees for non-CME/CE services: Amgen, Novartis.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

HCC: Treatment-Related Adverse Events, Case Discussions and Q&A – Episode 2

Fri, 25 Feb 2022 14:00:00 +0000

In this second episode of two podcasts, Dr. Amit Singal and Dr. Mark Yarchoan discuss how to identify, prevent and mitigate treatment-related adverse events, and review cases with careful considerations for patient-specific factors guiding treatment selection, followed by a question-and-answer session on the management of patients with HCC. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Amit Singal, MD, MS

Mark Yarchoan, MD

Bridget O’Brien, DNP, FNP-BC, AOCNP

Dr Singal: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Roche.

Dr Yarchoan: consulting fees: AstraZeneca, Eisai, Exelixis, Genentech; other financial or material support: Bristol-Myers Squibb, Incyte.

Dr O’Brien: fees for non-CME/CE services: Amgen, Novartis.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advanced Urothelial Cancer: Applying New Therapeutic Options, Part 2

Fri, 11 Feb 2022 14:50:00 +0000

In this second of two podcasts, discuss the management of advanced urothelial cancer with novel therapies and how to address adverse events, and concludes the episode with a review of audience questions and patient cases. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Arjun Balar, MD

Rana R. McKay, MD

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.

Dr McKay: consulting fees: AstraZeneca, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novarits, Sanofi, Sorrento Therapeutics; Vividion Therapeutics; consulting fees/contracted research: Bayer, Pfizer, Tempus.

Ms Sims: consulting fees: Coloplast.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advanced Urothelial Cancer: Applying New Therapeutic Options, Part 1

Fri, 11 Feb 2022 14:50:00 +0000

In this first of two podcasts, expert faculty review the latest data on the management of advanced urothelial cancer with novel therapies including immune checkpoint inhibitors and antibody-drug conjugates. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Arjun Balar, MD

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Ms Sims: consulting fees: Coloplast.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The New Array of Choices in Prostate Cancer—What’s Best for Your Patients? Part 1

Thu, 10 Feb 2022 19:15:00 +0000

In this first of two podcasts, Dr. Rana R. McKay discusses the optimal treatment selection and management of adverse events for patients with metastatic and nonmetastatic castration-sensitive prostate cancer (CRPC), including the use of taxanes, androgen receptor agonists, and other therapies.

This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Arjun Balar, MD

Rana R. McKay, MD

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Ms Sims: consulting fees: Coloplast.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The New Array of Choices in Prostate Cancer—What’s Best for Your Patients? Part 2

Thu, 10 Feb 2022 19:15:00 +0000

In this second of two podcasts, Rana R. McKay, MD, and Arjun Balar, MD, and moderator Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN, discuss the optimal treatment selection and management of adverse events for patients with metastatic and nonmetastatic castration-resistant or castration-sensitive prostate cancers, including the use of taxanes, androgen receptor agonists, and other therapies.

This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributor:

Arjun Balar, MD

Rana R. McKay, MD

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Ms Sims: consulting fees: Coloplast.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Pneumococcal Disease: Who, What, and When?

support@clinicaloptions.com (Martin C. Mahoney MD PhD, Tracey M. Piparo PA-C) — Thu, 10 Feb 2022 14:10:00 +0000

In this first of two podcasts, Tracey M. Piparo, PA-C and Martin C. Mahoney, MD, PhD discuss the benefits of pneumococcal vaccination, review the types of pneumococcal vaccines currently available, and provide ACIP’s recently updated age-based and risk-based recommendations on when to use the new conjugated pneumococcal vaccines. This activity is available for CE/CME credit. Claim your credit at pce.is/pneu.

Contributors:

Martin C. Mahoney, MD, PhD
Professor
Department of Epidemiology and Environmental Health
University of Buffalo
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Dr Mahoney: consulting fees: Pfizer; consulting fees/fees for non-CME/CE services: Merck; fees for non-CME/CE services: GlaxoSmithKline, Sanofi.

Tracey M. Piparo, PA-C
Palliative Medicine
RWJ Barnabas Health
New Brunswick, New Jersey
Immediate Past President
New Jersey State Society of Physician Assistants

Ms. Piparo has no relevant financial relationships to disclose.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Encouraging Pneumococcal Vaccination

support@clinicaloptions.com (Martin C. Mahoney MD PhD, Tracey M. Piparo PA-C) — Thu, 10 Feb 2022 14:10:00 +0000

In this second of two podcasts, Tracey M. Piparo, PA-C and Martin C. Mahoney, MD, PhD discuss barriers to pneumococcal vaccination, especially in the younger risk-based population, and provide specific strategies providers can implement to help improve pneumococcal vaccination coverage rates in effort to decrease the burden of pneumococcal disease. This activity is available for CE/CME credit. Claim your credit at pce.is/pneu.

Contributor:

Martin C. Mahoney, MD, PhD
Professor
Department of Epidemiology and Environmental Health
University of Buffalo
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Dr Mahoney: consulting fees: Pfizer; consulting fees/fees for non-CME/CE services: Merck; fees for non-CME/CE services: GlaxoSmithKline, Sanofi.

Tracey M. Piparo, PA-C
Palliative Medicine
RWJ Barnabas Health
New Brunswick, New Jersey
Immediate Past President
New Jersey State Society of Physician Assistants

Ms. Piparo has no relevant financial relationships to disclose.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

HPV Vaccination: Which Patients Are Eligible and When?

support@clinicaloptions.com (Martin C. Mahoney MD PhD, Tracey M. Piparo PA-C) — Wed, 9 Feb 2022 15:10:00 +0000

Tune into this informative conversation between Tracey M. Piparo, PA-C and Martin C. Mahoney, MD, PhD regarding the appropriate use of HPV vaccines for prevention of HPV-related cancers. Topics covered in this podcast include an overview of the burden of HPV, HPV vaccination coverage rates across different age groups, eligibility for HPV vaccination, and age-based dosing schedules. This activity is available for CE/CME credit. Claim your credit at pce.is/hpv.

Contributors:

Martin C. Mahoney, MD, PhD
Professor
Department of Epidemiology and Environmental Health
University of Buffalo
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Dr Mahoney: consulting fees: Pfizer; consulting fees/fees for non-CME/CE services: Merck; fees for non-CME/CE services: GlaxoSmithKline, Sanofi.

Tracey M. Piparo, PA-C
Palliative Medicine
RWJ Barnabas Health
New Brunswick, New Jersey
Immediate Past President
New Jersey State Society of Physician Assistants

Ms. Piparo has no relevant financial relationships to disclose.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Addressing Objections to HPV Vaccination

support@clinicaloptions.com (Martin C. Mahoney MD PhD, Tracey M. Piparo PA-C) — Wed, 9 Feb 2022 15:10:00 +0000

In this second of 2 podcasts, Tracey Piparo, PA-C and Martin C. Mahoney, MD, PhD provide strategies to overcome HPV vaccination barriers to improve our HPV vaccination rates among eligible individuals. The podcast includes a discussion of both provider and patient/caregiver barriers as well as specific strategies you can implement, including use of shared-decision making, to help prevent HPV-associated cancers through higher HPV vaccination rates. This activity is available for CE/CME credit. Claim your credit at pce.is/hpv.

Martin C. Mahoney, MD, PhD
Professor
Department of Epidemiology and Environmental Health
University of Buffalo
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Dr Mahoney: consulting fees: Pfizer; consulting fees/fees for non-CME/CE services: Merck; fees for non-CME/CE services: GlaxoSmithKline, Sanofi.

Tracey M. Piparo, PA-C
Palliative Medicine
RWJ Barnabas Health
New Brunswick, New Jersey
Immediate Past President
New Jersey State Society of Physician Assistants

Ms. Piparo has no relevant financial relationships to disclose.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Highlights from the American College of Rheumatology 2021 Annual Conference, Part 2

support@clinicaloptions.com (Robin Dore MD) — Fri, 17 Dec 2021 21:30:00 +0000

In this second of two podcasts, hear Dr Robin Dore discuss key information from ACR Convergence 2021, including the use of COVID-19 vaccine in immunosuppressed adults with autoimmune diseases; the cardiovascular risk of hydroxychloroquine in rheumatoid arthritis; whether the boxed warning for romosozumab helps prevent inappropriate use in postmenopausal women with osteoporosis and a history of myocardial infarction or stroke; how the incidence of cardiovascular events in patients with rheumatoid arthritis compares with that of patients with diabetes; and evaluating the risk of mortality in patients with suboptimally treated gout. This activity is available for CE/CME credit. Claim your credit at pce.is/ACR.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Highlights from the American College of Rheumatology 2021 Annual Conference, Part 1

support@clinicaloptions.com (Vibeke Strand MD MACR FACP) — Fri, 10 Dec 2021 16:02:57 +0000

In this first of two podcasts, hear Dr Vibeke Strand discuss key information from ACR Convergence 2021, including the potential to intervene in patients who are at high risk for developing rheumatoid arthritis; whether vitamin D3 and n-3 fatty acids can prevent autoimmune disease; the Food and Drug Administration’s perspective on the safety of Janus kinase inhibitors; and results from a phase 3b/4 randomized safety study of tofacitinib vs tumor necrosis factor inhibitors. This activity is available for CE/CME credit. Claim your credit at pce.is/ACR.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

CHEST Annual Meeting 2021 Conference Coverage, Part 2

Mon, 22 Nov 2021 21:15:09 +0000

In this second of 2 podcasts, Tish Haight, ACNP, CCRN, BC, and January-Jill Ogoy, DHSc, MPA, PA-C, provide clinical perspective on selected practice changing abstracts, covering a variety of topics from the CHEST 2021 Annual Meeting. Topics covered in this podcast include a chronic cough treatment in the pipeline, inhaled corticosteroid use and COVID-19 outcomes, and paradoxical bronchospasm with short-acting beta 2-agonists.. This activity is available for CE/CME credit. Claim your credit at pce.is/CHEST.

Contributors:

Tish Haight, ACNP, CCRN, BC
Pulmonary, Critical Care
Lung Associates of Sarasota
Sarasota, FL
Ms. Haight has no relevant financial relationships to disclose.

January-Jill Ogoy, DHSc, MPA, PA-C
APC, Pulmonary and Critical Care Medicine
Virginia Mason Franciscan Health
Tacoma, WA
Dr. Ogoy has no relevant financial relationships to disclose.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

CHEST Annual Meeting 2021 Conference Coverage – Part 1

Mon, 22 Nov 2021 21:14:45 +0000

In this first of 2 podcasts, Tish Haight, ACNP, CCRN, BC, and January-Jill Ogoy, DHSc, MPA, PA-C, provide clinical perspective on selected practice changing abstracts, covering a variety of topics from the CHEST 2021 Annual Meeting. Topics covered in this podcast include a comparison of idiopathic pulmonary arterial hypertension outcomes, an evaluation of combination therapies for the treatment of COPD, and the use of CPAP in patients hospitalized with COVID-19 pneumonitis. This activity is available for CE/CME credit. Claim your credit at pce.is/CHEST.

Contributors:

Tish Haight, ACNP, CCRN, BC
Pulmonary, Critical Care
Lung Associates of Sarasota
Sarasota, FL
Ms. Haight has no relevant financial relationships to disclose.

January-Jill Ogoy, DHSc, MPA, PA-C
APC, Pulmonary and Critical Care Medicine
Virginia Mason Franciscan Health
Tacoma, WA
Dr. Ogoy has no relevant financial relationships to disclose.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Atopic Dermatitis: Applying Expanding Treatment Options to Individual Patients

support@clinicaloptions.com (Robert Sidbury MD MPH, Morgan Maier PA-C BS) — Tue, 16 Nov 2021 15:07:10 +0000

In this podcast, an expert offers his perspective on the role of newer agents in atopic dermatitis—when they’re indicated, how to use them, where they fit on the therapeutic ladder, and adverse effects to monitor for. Also, tips on how to individualize therapy and anticipate adherence issues. The podcast concludes with thoughts on how to address some frequently-asked questions from patients and caregivers. This activity is available for CE/CME credit. Claim your credit at pce.is/AD.

Contributors:

Robert Sidbury, MD, MPH
Chief
Division of Dermatology
Seattle Children's Hospital
Professor
Department of Pediatrics
University of Washington School of Medicine
Seattle, Washington

Morgan Maier, PA-C, BS
Physician Assistant
Division of Dermatology
Seattle Children's Hospital
Seattle, Washington

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Individualizing Management of Uncontrolled Asthma: New Strategies, Part 2

support@clinicaloptions.com (Samuel Louie MD, Lawrence Herman DMSc MPA PA-C) — Fri, 29 Oct 2021 20:25:53 +0000

Targeted therapies address the underlying pathways that cause airflow obstruction in patients with asthma, including a number of biologic therapies that have been approved. Omalizumab targets IgE (approved for moderate to severe persistent asthma). Three agents target IL-5, which plays a key role in the activation of eosinophils, and are approved for severe eosinophilic asthma: mepolizumab, reslizumab, and benralizumab. Dupilumab targets IL-4/13 and has been approved for moderate to severe eosinophilic asthma or patients requiring maintenance OCS. All agents are available as subcutaneous injections administered at specific intervals, with the exception of reslizumab, which is available as an intravenous infusion. Selection of which biologic agent to use is dependent on multiple factors, including cost, dosing frequency, delivery route, and patient preference among other considerations. The GINA guidelines suggest a biologic agent should be given a trial of at least 4 months; if treatment response is unclear, clinicians should consider extending the trial another 6 to 12 months. If no response is noted, therapy should be changed to another biologic agent. These biologic therapies are generally safe and well tolerated; however, primary care clinicians seeing patients with asthma must be knowledgeable about common adverse events in order to recognize them.

Claim your credit here:
https://bit.ly/3pDx3NI

Contributors:

Lawrence Herman, DMSc, MPA, PA-C
Adjunct Faculty
Doctor of Medical Science Program
University of Lynchburg School of PA Medicine
Lynchburg, Virginia
President
Palantir Healthcare, LLC
Boiling Springs, South Carolina

Samuel Louie, MD
Professor Emeritus
Division of Pulmonary and Critical Care Medicine
University of California, Davis
Davis, California

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Individualizing Management of Uncontrolled Asthma: New Strategies, Part 1

support@clinicaloptions.com (Lawrence Herman DMSc MPA PA-C, Samuel Louie MD) — Fri, 29 Oct 2021 20:24:02 +0000

Asthma is now recognized as a heterogeneous, multidimensional disease that involves numerous pathophysiologic factors, including bronchiolar inflammation with airway constriction and resistance. The identification of distinct patient populations (phenotypes/endotypes) is increasingly being recognized as an important strategy for optimizing the management of patients with asthma. Asthma phenotype is based on clinical symptoms such as respiratory function, onset age, and blood biochemical examination values.

Clinical studies have shown that asthma phenotypes have specific patterns of inflammation that require different treatment approaches. For example, eosinophilic asthma is characterized by airway and systemic markers of eosinophilia, subepithelial fibrosis, and corticosteroid responsiveness, whereas non-eosinophilic asthma is characterized by the absence of eosinophilia and subepithelial fibrosis, as well as poor responsiveness to corticosteroids. In addition to high immunoglobulin (Ig) E levels in up to 60% of patients, asthma is characterized by tissue eosinophilia, which is mediated in part by interleukin (IL)-5. Because eosinophils produce inflammatory proteins that lead to tissue damage, the eosinophilic phenotype of asthma is associated with greater symptom severity, increased risk of exacerbation, and decreased lung function. The GINA guidelines recommend that asthma should be classified by phenotype, especially when it becomes difﬁcult to treat or refractory to treatment.

Claim your credit here:
https://bit.ly/3vUN7Mo

Contributors:

Lawrence Herman, DMSc, MPA, PA-C
Adjunct Faculty
Doctor of Medical Science Program
University of Lynchburg School of PA Medicine
Lynchburg, Virginia
President
Palantir Healthcare, LLC
Boiling Springs, South Carolina

Samuel Louie, MD
Professor Emeritus
Division of Pulmonary and Critical Care Medicine
University of California, Davis
Davis, California

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Optimizing IPF Care Through Improvements in Diagnosis, Treatment, and Shared Decision-Making

support@clinicaloptions.com (Corinne R. Young) — Wed, 13 Oct 2021 19:00:00 +0000

An early, accurate diagnosis and appropriate pharmacologic and nonpharmacologic treatment of IPF are imperative for improved outcomes. Given the poor prognosis of IPF, educating and involving patients in their care is necessary for optimal quality of life.

In this podcast, Corinne R. Young, MSN, FNP-C, FCCP, provides an overview of key points addressed by expert faculty during a live webinar. Please visit PCE.IS/ipf to view more activities on IPF.

Corinne R. Young, MSN, FNP-C, FCCP
Founder and President
Association of Pulmonary Advanced Practice Providers
Pulmonary Nurse Practitioner
Colorado Springs, Colorado

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Managing Influenza in the High-Risk Patient – Episode 2

support@clinicaloptions.com (Mary Knudtson NP, Michael G. Ison MD) — Thu, 19 Aug 2021 15:28:18 +0000

Effective influenza management during the COVID-19 pandemic requires a knowledge of emerging diagnostics, immunizations, and antiviral agents. The armamentarium for influenza treatment now includes multiple classes including neuraminidase inhibitors (eg, oseltamivir) and the polymerase acidic endonuclease inhibitor, baloxavir. In this podcast, Mary Knudtson, DNSc, NP, FAAN, asks questions from healthcare professionals to infectious disease expert, Michael G. Ison, MD, MS on timely, individualized influenza prevention and treatment. This activity is available for CE/CME credit. Claim your credit at pce.is/flu.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Managing Influenza in the High-Risk Patient – Episode 1

support@clinicaloptions.com (Tracy Zivin-Tutela MD, Lawrence Herman PAC) — Thu, 19 Aug 2021 15:17:01 +0000

Influenza management continues to increase in complexity as new diagnostic, prevention, and treatment options emerge and the COVID-19 pandemic adds additional considerations. Antiviral therapies for influenza now include neuraminidase inhibitors (eg, oseltamivir) and baloxavir. In this podcast, Lawrence Herman, DMSc, MPA, PA-C, asks timely influenza questions from healthcare professionals to infectious disease expert, Tracy Zivin-Tutela, MD. This activity is available for CE/CME credit. Claim your credit at pce.is/flu.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

SARS-CoV-2 Variants and the Future

support@clinicaloptions.com (John Hardisty PAC, Michael G. Ison MD) — Fri, 30 Apr 2021 21:39:29 +0000

In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.In this last episode of the 6-part series, an expert describes what is known about the SARS-CoV-2 variants—including the UK, South African, and Brazilian variants that are becoming more prevalent in the United States. The discussion then focuses on how these variants impact the efficacy of vaccines and monoclonal antibodies. Claim your credit at pce.is/COV19.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

EUAs and Vaccines

support@clinicaloptions.com (Michael G. Ison MD, John Hardisty PAC) — Fri, 30 Apr 2021 21:39:19 +0000

In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.This episode provides an overview of the rapid development of vaccines currently under Emergency Use Authorization (EUA) for the prevention of SARS-CoV-2 in the United States. An expert describes the mechanisms of action for the mRNA and viral vector vaccines, as well as efficacy, side effects, and post-vaccine safety assessment. The conversation concludes with a review of what is needed to achieve herd immunity, and guidance for people who are fully vaccinated. Claim your credit at pce.is/COV19.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A Look at EUA Outpatient Therapies

support@clinicaloptions.com (John Hardisty PAC, Michael G. Ison MS) — Fri, 30 Apr 2021 21:38:31 +0000

In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.In this fourth episode of the 6-part series, an expert explains what COVID-19 treatments are available in the outpatient setting. The focus is on monoclonal antibodies, bamlanivimab + etesevimab and casirivimab + imdevimab. For both drug combinations, he discusses the Emergency Use Authorization (EUA) indications, evidence on efficacy, and potential toxicities. Claim your credit at pce.is/COV19.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

EUAs: What’s Available Inpatient? Part 2

support@clinicaloptions.com (Paul G. Auwaerter MD, John Hardisty PAC) — Fri, 30 Apr 2021 21:36:59 +0000

In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.In this second half of a discussion about treatments for COVID-19 in the hospital setting, an expert explains the use of dexamethasone, including insights on the choice of steroids to treat COVID-19 in pregnancy. The conversation then moves to other immune modulators, tocilizumab and the combination of baricitinib plus the antiviral remdesivir, and includes an overview of the evidence on efficacy and safety.Claim your credit at pce.is/COV19.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

EUAs: What’s Available Inpatient? Part 1

support@clinicaloptions.com (John Hardisty PAC, Paul G. Auwaerter MD) — Fri, 30 Apr 2021 21:36:41 +0000

In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.This episode is the first half of an expert discussion on treatments for COVID-19 in the hospital setting. The episode covers the latest information on the use of convalescent plasma and remdesivir, including the available efficacy data, when to administer treatment, and potential toxicities to expect.Claim your credit at pce.is/COV19.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Understanding EUAs and Ensuring Safety When Time Is of the Essence

support@clinicaloptions.com (John Hardisty) — Fri, 30 Apr 2021 21:35:17 +0000

In this first of a 6-episode series on Emergency Use Authorization (EUA) in COVID-19, an expert explains the differences between EUA and full approval, how long EUAs last, and how new clinical trial evidence supports and changes an EUA. The discussion concludes with an overview of safety and management of potential adverse events. Claim your credit at pce.is/COV19.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

GLP-1 RAs: Which Ones for Which Patients?

support@clinicaloptions.com (Anne Peters MD, Davida Kruger MSN) — Fri, 26 Mar 2021 17:19:14 +0000

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now firmly established as guideline-recommended antiglycemic agents of choice in patients with type 2 diabetes, especially when comorbid disease is evident or when the patient is at high risk for such conditions. Join Davida Kruger, NP and Anne Peters, MD for a lively discussion on the use of GLP-1 RAs in clinical practice, including how to use shared decision-making to choose an ideal agent based on patient, disease, and GLP-1 RA characteristics. The unique effects of GLP-1 RAs on cardiovascular disease and weight mitigation are also discussed in the context of patient selection and management.

This episode is available for CE/CME credit.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

GLP-1 RAs: What Patients Need To Know

support@clinicaloptions.com (Davida Kruger MSN, Anne Peters MD) — Fri, 26 Mar 2021 17:18:59 +0000

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now firmly established as guideline-recommended antiglycemic agents of choice in patients with type 2 diabetes, especially when comorbid disease is evident or when the patient is at high risk for such conditions. In this second of two podcasts, Davida Kruger, NP and Anne Peters, MD share tips and pearls for treating patients with type 2 diabetes using GLP-1 RAs, including when to choose a GLP-1 RA, how to broach the topic of a first injectable, when an oral agent is preferred, strategies for encouraging lifestyle modifications, and practical advice on preparing and monitoring patients with respect to GLP1-RA therapy.

This episode is available for CE/CME credit.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Managing Pulmonary Arterial Hypertension

Mon, 15 Feb 2021 19:38:09 +0000

A number of specific therapies are now available for pulmonary arterial hypertension (PAH), and the outlook for patients with PAH has never been better. But first PAH must be differentiated from the other forms of pulmonary hypertension. In this podcast, Corinne Young, FNP-C, president of the Association of Pulmonary Advanced Practice Providers, talks with pulmonary hypertension expert Martha Kingman, FNP-C, DNP, about establishing the diagnosis of PAH, determining the subcategory of PAH, today’s approach to management, and the important role of primary care NPs and PAs in long-term follow-up. This activity is available for CE/CME credit.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Identifying and Managing the Subtypes of Pulmonary Hypertension

Mon, 15 Feb 2021 19:37:36 +0000

All pulmonary hypertension is not the same, and it’s important to differentiate among the five different subtypes to ensure effective management. In this podcast, Corinne Young, FNP-C, president of the Association of Pulmonary Advanced Practice Providers, talks with pulmonary hypertension expert Martha Kingman, FNP-C, DNP, about the classification system for pulmonary hypertension, how to distinguish the five subtypes clinically, and best practices in management. This episode is available for CE/CME credit.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Updates in Insomnia: A Focus on Orexin Receptor Antagonism

support@clinicaloptions.com (Karl Doghramji MD) — Tue, 3 Nov 2020 21:23:53 +0000

In this episode, Karl Doghramji, MD, Medical Director at the Jefferson Sleep Disorders Center in Philadelphia, talks to clinicians about the newest class of pharmacologic agents, orexin receptor antagonists, for the treatment of insomnia. He also discusses how to recognize signs, symptoms, and risk factors that should trigger screening, differentiation of the different types of sleep disorders, and lifestyle measures that should be part of any treatment.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Reducing the Burden of Endometriosis: The Role of Primary Care

support@clinicaloptions.com (Diana Atashroo MD) — Tue, 27 Oct 2020 18:18:08 +0000

In this episode, Diana Atashroo, MD, a specialist in endometriosis treatment, gives expert advice on how to recognize and treat endometriosis early, before it transitions to daily, chronic pain and a centralized pain state. She also provides recommendations for long-term management and coordination of care.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Managing Uncontrolled Asthma: the Primary Care/Specialist Partnership

Mon, 19 Oct 2020 20:54:32 +0000

Primary care practitioners play a major role in the management of asthma, providing diagnosis, patient education, and management plans. But when the asthma remains uncontrolled, management can be challenging. On this podcast, Corinne Young FNP-C, president of the Association of Pulmonary Advanced Practice Providers speaks with asthma expert Ann Hefel, FNP-C of Children's Hospital Colorado about what clinicians have in their therapeutic toolbox to help patients with moderate to severe disease whose asthma remains uncontrolled despite adequate therapy. This activity is available for CE/CME credit.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How to Recognize Whether Your Patient’s Asthma Is Uncontrolled

Mon, 19 Oct 2020 20:54:25 +0000

As many as 20% of patients with asthma may not be achieving adequate control of their symptoms, even after they have maximized inhaled corticosteroids and their long-acting beta 2 agonist. If left uncontrolled, patients are at increased risk for serious exacerbations that can lead to ED visits and extended hospitalizations. In this podcast, Corinne Young, FNP-C, president of the Association of Pulmonary Advanced Practice Providers, talks with her colleague Ann Hefel, FNP, an allergy and asthma specialist from Children’s Hospital Colorado about reasons for poor asthma control and how to conduct an effective patient workup to identify the potential causes. This episode is available for CE/CME credits for NPs and PAs.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Chronic Idiopathic Constipation

support@clinicaloptions.com (Brooks D. Cash MD) — Thu, 1 Oct 2020 19:49:28 +0000

In this episode, Dr. Brooks Cash provides an expert look at chronic idiopathic constipation, how to differentiate it from a commonly confused condition, irritable bowel syndrome, and when diagnosed what treatment options are available, both nonpharmacologic and pharmacologic.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.